It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it happened in INmune Bio, Inc.'s (NASDAQ:INMB) case, it's fantastic news for shareholders.

While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.

Check out our latest analysis for INmune Bio

INmune Bio Insider Transactions Over The Last Year

In the last twelve months, the biggest single purchase by an insider was when Independent Director Scott Juda bought US$246k worth of shares at a price of US$8.32 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$5.00). Their view may have changed since then, but at least it shows they felt optimistic at the time. In our view, the price an insider pays for shares is very important. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.

INmune Bio insiders may have bought shares in the last year, but they didn't sell any. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

INmune Bio is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.

INmune Bio Insiders Bought Stock Recently

It's good to see that INmune Bio insiders have made notable investments in the company's shares. In total, insiders bought US$200k worth of shares in that time, and we didn't record any sales whatsoever. This could be interpreted as suggesting a positive outlook.

Insider Ownership

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 20% of INmune Bio shares, worth about US$23m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

What Might The Insider Transactions At INmune Bio Tell Us?

The recent insider purchases are heartening. And the longer term insider transactions also give us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. When combined with notable insider ownership, these factors suggest INmune Bio insiders are well aligned, and that they may think the share price is too low. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Case in point: We've spotted 3 warning signs for INmune Bio you should be aware of, and 1 of them is significant.